RB1 and cancer: RB1 dysfunction, resulting from mutations, deletions, transcriptional silencing or hyperphosphorylation, significantly contributes to cancer development, particularly in TNBC, where approximately 30% of patients exhibit loss or downregulation of RB1 expression [9, 10].